Pacific Biosciences of California (PACB) has just posted its FY 2025 numbers, with Q4 revenue at US$44.6 million and a basic EPS loss of US$0.13 set against trailing twelve month revenue of US$160.0 million and a TTM basic EPS loss of US$1.82. Over the past six reported quarters, the company has seen quarterly revenue move between US$37.2 million and US$44.6 million, while basic EPS has ranged from a small profit of US$0.01 in FY 2024 Q4 to a loss of US$1.44 in FY 2025 Q1. This leaves investors focused squarely on how margins and loss levels evolve from here.

See our full analysis for Pacific Biosciences of California.

With the headline figures on the table, the next step is to see how these results line up with the most widely held narratives about Pacific Biosciences' growth potential, risk profile, and path toward more efficient margins.

TTM losses of US$546 million keep profitability in focus

• Over the trailing twelve months to FY 2025 Q4, Pacific Biosciences reported total revenue of US$160.0 million against a net loss of US$546.4 million, with TTM basic EPS at a loss of US$1.82.
• Consensus narrative points to expanding global genomics and clinical use as long term earnings drivers, yet the current loss level tests that view:
  • Analysts reference growing adoption in national genomics initiatives and clinical labs. However, TTM revenue growth of 10.9% per year is only slightly below the broader US market growth rate of 11.4%, so the gap between revenue and losses remains wide.
  • Forecasts still show the company remaining unprofitable over the next three years. Any thesis built around future margin improvement therefore has to be weighed against the current US$546.4 million TTM loss.

Quarterly net losses between US$38 million and US$41 million after Q1 spike

• After a very large Q1 FY 2025 net loss of US$426.1 million, net losses in Q2 to Q4 FY 2025 sit in a much narrower band between US$38.0 million and US$41.9 million, while quarterly revenue over that stretch ranges from US$37.2 million to US$44.6 million.
• Bulls argue that higher consumables usage and clinical adoption can support better margins over time, and these steadier quarterly loss figures are one test of that claim:
  • The move from a small profit of US$2.4 million in FY 2024 Q4 to consistent quarterly losses of around US$40 million in FY 2025 shows that, despite revenue holding near US$40 million per quarter, the cost base still outweighs sales by a wide margin.
  • With trailing losses having grown at about 35.3% per year over the past five years, the bullish idea of structurally higher margins from new products and higher consumables mix has not yet translated into positive net income in the reported numbers.

Bulls suggest the current earnings drag might set up a stronger long term story if consumables and clinical use keep building, so it can be helpful to see how that thesis is laid out in detail before deciding what the latest numbers mean for you. 🐂 Pacific Biosciences of California Bull Case

P/S of 3.2x vs peers and insider selling tension

• The stock trades on a P/S of 3.2x, which sits below the US Life Sciences industry average of 3.4x and below a peer average of 4.5x, while the share price of US$1.65 is being compared to an analyst target of US$2.38 and a DCF fair value of US$1.63.
• Bears point to continued losses and insider selling as key risks that can justify a lower multiple despite revenue growth:
  • Forecasts indicate the company is expected to remain unprofitable for at least the next three years, and cumulative losses have increased at about 35.3% per year over the past five years, which aligns with a cautious view on future earnings power.
  • Significant insider selling over the past three months sits alongside the below peer P/S multiple, which critics see as consistent with a market that is already pricing in execution risk despite the 10.9% trailing revenue growth rate.

Skeptical investors often focus on how persistent losses and insider selling fit with the current P/S discount, so reviewing that cautious argument in full can help you decide how much weight to put on the risks. 🐻 Pacific Biosciences of California Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Pacific Biosciences of California on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With all of that in mind, are you leaning bullish or cautious on Pacific Biosciences based on these figures and narratives so far? Move quickly, review the data for yourself, and look at the 2 important warning signs.

See What Else Is Out There

Pacific Biosciences is still posting sizeable TTM losses of US$546.4 million alongside quarterly losses of around US$40 million, which keeps profitability and risk firmly in focus.

If you are uneasy about that level of ongoing losses and want ideas with steadier financial profiles, check out the 72 resilient stocks with low risk scores to find stocks where downside risk is more tightly controlled.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.